BofA raised the firm’s price target on Amphastar (AMPH) to $32 from $28 and keeps a Neutral rating on the shares after increasing near-term forecasts to reflect the recent generic Venofer approval. Generic Venofer “looks like a good, but not great, generic product due to competitive dynamics at market formation,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Amphastar Pharmaceuticals’ Mixed Earnings Call Highlights
- Amphastar Pharmaceuticals: Strategic Positioning and Robust Pipeline Justify Buy Rating
- Amphastar announced FDA approval of iron sucrose injection
- Needham upgrades Amphastar on valuation post AMP-002 approval
- Amphastar upgraded to Buy from Hold at Needham